Optimal vitamin D levels: what the guidelines actually say

Vitamin D from sun exposure, food and supplements is biologically inactive. The liver converts it into 25-hydroxyvitamin D, or 25(OH)D, which the NIH Office of Dietary Supplements (ODS) describes as the main indicator of vitamin D status. 25(OH)D has a fairly long circulating half-life of about 15 days, which is why it is the form measured in the 25-hydroxyvitamin D test.

Labs report vitamin D levels in either ng/mL or nmol/L. One ng/mL equals 2.5 nmol/L, so 20 ng/mL and 50 nmol/L are the same value. Mixing the two units in one trend makes values hard to compare.

The ODS fact sheet for health professionals summarizes the thresholds from the Food and Nutrition Board (FNB) of the National Academies. The ODS is explicit that the concentrations associated with deficiency have not been definitively identified. The bands below are the conclusions of an FNB expert committee.

The same fact sheet states that optimal serum concentrations of 25(OH)D for bone and general health have not been established, because they are likely to vary by stage of life, by race and ethnicity and with the physiological measure used. It also notes that the FNB found the evidence on outcomes other than bone health inadequate or too contradictory to draw conclusions.

In June 2024 the Endocrine Society published Vitamin D for the Prevention of Disease, which updates and replaces its 2011 guideline on evaluating, treating and preventing vitamin D deficiency. The new guideline addresses people without established indications for vitamin D treatment or 25(OH)D testing.

• The panel found no clinical trial evidence to support routine 25(OH)D screening in the general population, or in people with obesity or dark complexion, and suggests against routine testing in all populations it considered.
• It found no clear evidence defining an optimal target level of 25(OH)D for disease prevention in those populations.
• In a companion guideline communication, the Society states it no longer endorses its earlier definitions of sufficiency (at least 30 ng/mL, or 75 nmol/L) or insufficiency (above 20 but below 30 ng/mL).
• The recommendations do not replace the Dietary Reference Intakes and do not apply to people with established indications for vitamin D treatment or testing.

The guideline's other recommendations concern supplementation in specific groups. Those are clinical decisions outside the scope of this page.

Part of the confusion around optimal vitamin D levels comes from the 30 ng/mL figure. It came from the Endocrine Society's 2011 guideline, and the Society no longer endorses it. The positions side by side:

On intake guidelines, the ODS attributes the differences between bodies to an incomplete understanding of vitamin D biology, guidelines written for different purposes (public health versus clinical practice) and the use of observational studies alongside randomized trials in some of them. The Endocrine Society's 2024 communication makes a similar point about thresholds: earlier proposals rested largely on observational studies, which give weaker evidence than randomized trials. Laboratories and guidelines still differ, so check which thresholds a lab prints on its report.

The ODS notes that measuring 25(OH)D is complicated by considerable variability between the available assays, the two most common of which use antibodies or chromatography. A result can be falsely low or falsely high depending on the assay and the lab. The international Vitamin D Standardization Program has developed procedures to standardize 25(OH)D measurement.

Since neither the FNB (as summarized by ODS) nor the Endocrine Society has established an optimal 25(OH)D level, a longevity clinic that uses an optimal band is making its own clinical decision. That is legitimate, and it is easier to defend when it is written down.

• State which body or evidence the band follows, and say so in the patient-facing explanation.
• Pick one unit for the biomarker and keep it.
• Decide whether the band has an upper bound, and note the FNB's adverse-effects threshold when you set it.
• Review the band when guidance changes, as it did in 2024.

Our guide to optimal vs reference ranges covers how to set, document and revisit clinic ranges.

In LongevityEHR your clinic sets its own range for vitamin D, per sex if you choose, and every released value is graded against it and added to a trend across draws. Each value keeps a snapshot of the range that applied when it was recorded, so if your clinic revises its band after a guideline change, past results keep the grade they had. See biomarker tracking.

Results arrive through AI lab extraction. Upload a lab PDF or image and the 25(OH)D value is matched to your vitamin D biomarker. A report in nmol/L against a biomarker configured in ng/mL is flagged for review and never silently converted. A provider reviews and releases every result before the patient sees it.

LongevityEHR does not interpret results or recommend doses. Your providers write the interpretation, and any plan changes live in the patient's care plan. For another marker where cutoffs depend on the guideline and its purpose, see ferritin.